The Patent Finder

Centre Leon Berard

35 patents currently held · Updated Nov 21, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

1
Ending by 2030
Dec 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 28, 2027
    The maintenance fee for Early and Non Invasive Method for Assessing a Subject's Risk of Having Pancreatic Ductal Adenocarcinoma and Methods of Treatement of Such Disease (US 11,740,243) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Apr 30, 2027
    The maintenance fee for Therapy Apparatus for Treating Tissue by the Emission of Remote Crossed Focused Ultrasound Waves (US 11,801,400) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
  • 1 fee due Jul 14, 2027
    The maintenance fee for ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers (US 10,533,046) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Antibodies Directed Against ICOS and Uses Thereof (US 10,633,446) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,203,641Screening for Anti-Cancer Compounds Using NETRIN-1 Activity
In force
 · Medium confidence
In forceMedium confidence
US 9,676,852Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,975,950Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,633,446Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,745,482Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,376,493Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,004,888Method for Determining Optimized Parameters of a Device Generating a Plurality of Ultrasound Beams Focused in a Region of Interest
In force
 · High confidence
In forceHigh confidence
US 9,683,986Treatment of Cancer by Inhibition of the MYD88/ERK Map Kinase Interaction
In force
 · High confidence
In forceHigh confidence
US 11,180,556Antibodies Directed Against ICOS and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,895,439Combined Treatment with Netrin-1 Interfering Drug and Chemotherapeutic Drug
In force
 · High confidence
In forceHigh confidence
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
Also on record, not counted in the 35: 4 patents in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

21 pending · 20 abandoned · 1 no status recorded

Showing 1 to 10 of 42, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/886,180Combined Treatment with NETRIN-1 Interfering Drug and Immune Checkpoint Inhibitors DrugsSep 16, 2024Pending
18/634,088Method for Generating a Registered ImageApr 12, 2024Abandoned
18/592,164Stable Clonal Cell Line as a HBV Rna StandardFeb 29, 2024Pending
18/340,054Use of FUBP1 Inhibitors for Treating Hepatitis B Virus InfectionJun 23, 2023Pending
18/853,766Xophos Inhibitors for Use in the Treatment of B-Cell LymphomaApr 7, 2023Pending
18/832,712New Method for Identifying Herv-Derived EpitopesJan 25, 2023Pending
18/721,954T Cell Progenitor Having Controlled Expression of a Transgene of InterestDec 21, 2022Pending
18/713,383TRANSCRIPTOMIC SIGNATURE BASED ON HERVs EXPRESSION TO CHARACTERIZE LEUKEMIC STEM CELLS AND USEFUL AS A LSC MARKERNov 25, 2022Pending
18/713,351USE OF A TRANSCRIPTOMIC SIGNATURE BASED ON HERVs EXPRESSION TO CHARACTERIZE NEW ACUTE MYELOID LEUKEMIA SUBTYPESNov 25, 2022Pending
18/708,656A Numerical Method for the Separation of Shear Compression Waves in a Displacement Vector FieldNov 15, 2022Pending
10 of 42 applications shown.
Pro members see all 42 published applications.
Pro members: see all 42 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited